Overview

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

Status:
Completed

Trial end date:
1991-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol, in patients with chronic schizophrenia.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen, LP

Treatments:

Haloperidol
Haloperidol decanoate
Risperidone